J
Javier P. Gisbert
Researcher at Autonomous University of Madrid
Publications - 1076
Citations - 39753
Javier P. Gisbert is an academic researcher from Autonomous University of Madrid. The author has contributed to research in topics: Helicobacter pylori & Inflammatory bowel disease. The author has an hindex of 95, co-authored 990 publications receiving 33726 citations. Previous affiliations of Javier P. Gisbert include Services Hospital & University of Alcalá.
Papers
More filters
Journal ArticleDOI
Influence of CYP2C8 and CYP2C9 polymorphisms on pharmacokinetic and pharmacodynamic parameters of racemic and enantiomeric forms of ibuprofen in healthy volunteers.
Rosario López-Rodríguez,Jesús Novalbos,Sonia Gallego-Sandín,Manuel Román-Martínez,Juan J. Torrado,Javier P. Gisbert,Francisco Abad-Santos +6 more
TL;DR: This study suggest an impaired metabolism of racemic, S-ibuprofen and R-ib uprofen in CYP2C9*3; an increased R-IBuproen metabolism in CYC2C8*3 volunteers; and fewer adverse events in CYp2C 8*3 Volunteers; that correlates with a decreased expression of iNOS.
Journal ArticleDOI
What is the optimal length of proton pump inhibitor-based triple therapies for H. pylori? A cost-effectiveness analysis.
TL;DR: Triple therapy with a proton pump inhibitor, clarithromycin and amoxicillin is widely used for H. pylori infection and the appropriate length of treatment remains controversial.
Journal ArticleDOI
¿Cómo realizar, evaluar y utilizar revisiones sistemáticas y metaanálisis?
Javier P. Gisbert,Xavier Bonfill +1 more
TL;DR: Hoy más que nunca existen diversos motivos that hacen necesario gestionar correctamente el conocimiento, el futuro se promete imparable en cuanto a the expansión continua of the información obtenida mediante la investigación.
Journal ArticleDOI
Treatment of Helicobacter pylori infection 2011.
TL;DR: A review of the literature published pertaining to Helicobacter pylori eradication over the last year can be found in this article, where a clear evidence now exists that both levofloxacin and bismuth are viable options for first-line therapy.
Journal ArticleDOI
Effectiveness of adalimumab in perianal fistulas in crohn's disease patients naive to anti-TNF therapy.
Carlos Castaño-Milla,María Chaparro,Cristina Saro,Manuel Barreiro-de Acosta,Ana M. Garcia-Albert,Luis Bujanda,María Dolores Martín-Arranz,Daniel Carpio,Fernando Muñoz,Noemí Manceñido,Esther Garcia-Planella,M Piqueras,Xavier Calvet,José Luis Cabriada,B. Botella,Fernando Bermejo,Javier P. Gisbert +16 more
TL;DR: A good correlation between clinical and radiologic assessment of therapy response was found and ADA was effective for the treatment of perianal fistulas in CD patients naive to anti-TNF drugs.